Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout - PubMed (original) (raw)

Review

Rasburicase represents a new tool for hyperuricemia in tumor lysis syndrome and in gout

Lisa Cammalleri et al. Int J Med Sci. 2007.

Abstract

Hyperuricemia is a feature of several pathologies and requires an appropriate and often early treatment, owing to the severe consequences that it may cause. A rapid and massive raise of uric acid, during tumor lysis syndrome (TLS), and also a lower and chronic hyperuricemia, as in gout, mainly damage the kidney. To prevent or treat these consequences, a new therapeutic option is represented by rasburicase, a recombinant form of an enzyme, urate oxidase. This enzyme converts hypoxanthine and xanthine into allantoin, a more soluble molecule, easily cleared by kidney. The several types of urate oxidase have followed each other, with progressive reduction of adverse reactions. The most important among them are allergenicity and the development of antibodies which compromise their effectiveness. Nevertheless, a limit of rasburicase's use remains its cost, which obliges to a judicious choice to prevent TLS in high risk patients with cancer and in case of allergy or impossibility to take allopurinol orally both in TLS and in gout. A large body of evidence confirms the efficacy and safety of rasburicase, even in comparison to the standard drugs used in the aforementioned pathologies.

PubMed Disclaimer

Conflict of interest statement

Conflict of interests: The authors have declared that no conflict of interest exists.

Figures

Figure 1

Figure 1

The systemic effects of cellular lysis and the consequent vicious circle that worsens renal functionality

Figure 2

Figure 2

Multifactorial pathogenesis of ARF (Acute Renal Failure)

Similar articles

Cited by

References

    1. Cairo MS, Bishop M. Tumour lysis syndrome: new therapeutic strategies and classification. Br J Haematol. 2004;127:3–11. - PubMed
    1. Choi HK, Mount DB, Reginato AM. American College of Physicians, American Physiological Society Pathogenesis of gout. Ann Intern Med. 2005;143:499– 516. - PubMed
    1. Campion EW, Glynn RJ, Delabry LO. Asyntomatic hyperuricemia. Risks and consequences in the Normative Aging Study. Am J Med. 1987;82:421–426. - PubMed
    1. Lin KC, Lin HY, Chou P. The interaction between uric acid level and other risk factors on the development of gout among asyntomatic hyperuricemic men in a prospective study. Journal of Rheumatology. 2000;27:1501– 1505. - PubMed
    1. Leusmann DB. A classification of urinary calculi with respect to their composition and micromorphology. Scand J Urol. 1991;25:141–50. - PubMed

Publication types

MeSH terms

Substances

LinkOut - more resources